Nano Tsunami : New Nanotech Device Could Revolutionize Blood Testing

New Nanotech Device Could Revolutionize Blood Testing

Like the small fingerstick devices that have revolutionized management of insulin therapy for people with diabetes, BioSensus, Inc., is developing a rapid and inexpensive monitor for anticoagulant therapy that could make a major difference for millions of patients.

It could also send BioSensus over the top as an overnight success in the medical device industry. The company is eying a $1 billion blood coagulation and hemostatic assay market, according to NanoBiotech News, the only weekly, independent news source on the business and science of nanomedicine development.

Worldwide, about 6 million people are treated with oral anticoagulant therapy to prevent the formation of blood clots in atrial fibrillation, deep vein thrombosis, heart attack, stroke and other potentially life-threatening conditions. In American hospitals, hundreds of thousands of patients receive intravenous heparin therapy on a temporary basis, to reduce the risk of clots….read the wave www.nano-tsunami.com